Apremilast: drug information. 2016 [cited 2016 May 16]. In: UpToDate [Internet]. Waltham (MA): UpToDate; 1992 -. Available from: www​.uptodate.com Subscription required.

Feldman SR. Treatment for psoriasis. 2016 [cited 2016 May 16]. In: UpToDate [Internet]. Waltham (MA): UpToDate; 1992 -. Available from: www​.uptodate.com Subscription required.

Clinical study report no. CC-10004-PSOR-009. A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis [CONFIDENTIAL internal manufacturer’s report]. Summit (NJ): Celgene Corporation; 2013 Jul 8.

Clinical study report no. CC-10004-PSOR-008. A phase 3, multicenter, randomized, double-blind, placebo-controlled, efficacy and safety study of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis [CONFIDENTIAL internal manufacturer’s report]. Summit (NJ): Celgene Corporation; 2013 Jul 3.

Clinical Study Report: CC-10004-PSOR-010. A phase 3b, multicenter, randomized, placebo-controlled, double-blind, double-dummy, study of the efficacy and safety of apremilast (cc-10004), etanercept, and placebo, in subjects with moderate to severe plaque psoriasis [CONFIDENTIAL internal manufacturer’s report]. Summit (NJ): Celgene Corporation; 2014 Oct 13.

Canadian Dermatology Association [Internet]. Ottawa (ON): Canadian Dermatology Association; c2016. Psoriasis. Living with psoriasis; 2016 [cited 2016 May 16]. Available from: http://www​.dermatology​.ca/skin-hair-nails​/skin/psoriasis/#!/skin-hair-nails​/skin​/psoriasis/living-with-psoriasis/

Levy AR, Davie AM, Brazier NC, Jivraj F, Albrecht LE, Gratton D, et al Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012 Dec;51(12):1432–40. [PubMed: 23171010]

CPS [Internet]. Ottawa: Canadian Pharmacists Association; 2016. [cited 2016 May 25]. Available from: http://www​.e-therapeutics.ca

Otezla® (apremilast) tablets 10 mg, 20 mg, and 30 mg [product monograph]. Mississauga (ON): Celgene Inc.; 2015 Jun 9.

Taltz™ (ixekizumab): solution for injection 80mg/1.0 mL [product monograph] [Internet]. Toronto (ON): Eli Lilly Canada Inc.; 2016. [cited 2016 Jun 1]. Available from: http://www​.lilly.ca/en​/pdf/product-monograph​/taltz-pm-english.pdf

CADTH Canadian Drug Expert Committee (CDEC) final recommendation. Apremilast (Otezla - Celgene). Indication: moderate to severe plaque psoriasis. [Internet]. Ottawa: CADTH; 2015. [cited 2016 Apr 26]. Available from: https://www​.cadth.ca​/sites/default/files​/cdr/complete/SR0400-Otezla-Aug-10-15-e​.pdf

Celgene Corporation response to April 12, 2016 CDR request for additional information regarding the Otezla resubmission CDR review: LIBERATE study [CONFIDENTIAL additional manufacturer’s information]. Summit (NJ): Celgene Corporation; 2016 Apr 25.

CDR submission: Otezla® (apremilast) for the treatment of moderate to severe plaque psoriasis, 10 mg, 20 mg, and 30 mg oral tablets [Resubmission]. Company: Celgene Inc. [CONFIDENTIAL manufacturer’s submission]. Mississauga (ON): Celgene Inc.; 2016 Mar 3.

Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Medical review(s). In: Otezla (apremilast). Company: Celgene Corp. Application no.: 206088. Approval date: 23/09/2014 [Internet]. Rockville (MD): FDA; 2014 Sep 23 [cited 2016 Apr 4]. (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2014/206088Orig1s000TOC.cfm

Center for Drug Evaluation and Research, U.S. Food and Drug Administration. Statistical review(s). In: Otezla (apremilast). Company: Celgene Corp. Application no.: 206088. Approval date: 23/09/2014 [Internet]. Rockville (MD): FDA; 2014 Sep 23 [cited 2016 Apr 4]. (FDA drug approval package). Available from: http://www​.accessdata​.fda.gov/drugsatfda_docs​/nda/2014/206088Orig1s000TOC.cfm

Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol. 2003 Aug;49(2):206–12. [PubMed: 12894066]

Heredi E, Rencz F, Balogh O, Gulacsi L, Herszenyi K, Hollo P, et al Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ. 2014 May;15 Suppl 1:S111-S119. [PubMed: 24832842]

Revicki D, Willian MK, Saurat JH, Papp KA, Ortonne JP, Sexton C, et al Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2008 Mar;158(3):549–57. [PubMed: 18047521]

Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr;22(2):65–74. [PubMed: 20443663]

Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar;50(3):416–30. [PubMed: 14988684]

Silva MF, Fortes MR, Miot LD, Marques SA. Psoriasis: correlation between severity index (PASI) and quality of life index (DLQI) in patients assessed before and after systemic treatment. An Bras Dermatol. 2013 Sep;88(5):760–3. [PMC free article: PMC3798353] [PubMed: 24173182]

Schafer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol. 2010 Jan;20(1):62–7. [PubMed: 19822480]

Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014 Mar;28(3):333–7. [PubMed: 23425140]

Ruderman EM, Markenson JA. Granulomatous infections and tumor necrosis factor antagonist therapies [abstract]. Poster presented at: EULAR; 2003 Jun 18; Lisbon, Portugal.

Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. Health Qual Life Outcomes [Internet]. 2006 [cited 2016 Apr 25];4:71. Available from: http://www​.ncbi.nlm.nih​.gov/pmc/articles​/PMC1615869/pdf/1477-7525-4-71.pdf [PMC free article: PMC1615869] [PubMed: 17005043]

Feldman SR, Menter A, Koo JY. Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. Br J Dermatol. 2004 Feb;150(2):317–26. [PubMed: 14996104]

Weisman S, Pollack CR, Gottschalk RW. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis. J Dermatolog Treat. 2003 Sep;14(3):158–65. [PubMed: 14522626]

Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol. 1999 Aug;141(2):185–91. [PubMed: 10468786]

Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004 Jun;50(6):859–66. [PubMed: 15153885]

Gourraud PA, Le GC, Puzenat E, Aubin F, Ortonne JP, Paul CF. Why statistics matter: limited inter-rater agreement prevents using the psoriasis area and severity index as a unique determinant of therapeutic decision in psoriasis. J Invest Dermatol. 2012 Sep;132(9):2171–5. [PubMed: 22592157]

Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The Psoriasis Symptom Diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014 Jun;53(6):714–22. [PubMed: 23557000]

Strober BE, Nyirady J, Mallya UG, Guettner A, Papavassilis C, Gottlieb AB, et al Item-level psychometric properties for a new patient-reported psoriasis symptom diary. Value Health. 2013 Sep;16(6):1014–22. [PubMed: 24041351]

Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol. 2006 Apr;54(4):685–704. [PubMed: 16546593]

Frendl DM, Ware JE, Jr. Patient-reported functional health and well-being outcomes with drug therapy: a systematic review of randomized trials using the SF-36 health survey. Med Care. 2014 May;52(5):439–45. [PubMed: 24714581]

Simpson MJ, Chow C, Morgenstern H, Luger TA, Ellis CN. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician’s Global Assessment, Psoriasis Area and Severity Index and Static Physician’s Global Assessment. J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1415–20. [PubMed: 25917214]

Basra MKA, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035. [PubMed: 18795920]

Fernandez-Penas P, Jones-Caballero M, Espallardo O, Garcia-Diez A. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. Br J Dermatol. 2012 Apr;166(4):884–7. [PubMed: 22229951]

Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician’s Global Assessment. J Am Acad Dermatol. 2004 Oct;51(4):563–9. [PubMed: 15389191]

Cappelleri JC, Bushmakin AG, Harness J, Mamolo C. Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res. 2013 Nov;22(9):2489–99. [PubMed: 23475691]

Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl 2):ii65-ii68. [PMC free article: PMC1766877] [PubMed: 15708941]

Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol. 2003 Aug;49(2 Suppl):S57-S61. [PubMed: 12894127]

Hani AF, Prakasa E, Nugroho H, Affandi AM, Hussein SH. Body surface area measurement and soft clustering for PASI area assessment. Conf Proc IEEE Eng Med Biol Soc. 2012;4398–401. [PubMed: 23366902]

Jacobson CC, Kimball AB. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased. Br J Dermatol. 2004 Aug;151(2):381–7. [PubMed: 15327545]

Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nyirady J, Papavassilis C, et al Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. Int J Dermatol. 2016 Mar;55(3):e147-e155. [PubMed: 26518255]

Norlin JM, Steen CK, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012 Apr;166(4):797–802. [PubMed: 22182212]

Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia HA, et al A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007 Apr;56(4):598–603. [PubMed: 17113190]

PSO network meta-analysis report - a supplemental document to the Otezla® (apremilast) pharmacoeconomic evaluation report. In: CDR submission: Otezla® (apremilast), 10mg, 20mg, 30 mg tablets. Company: Celgene Inc. [CONFIDENTIAL manufacturer’s submission]. Mississauga (ON): Celgene Inc.; 2014 Oct.